Emerging Technology as a Key Enabler for Modernizing Pharmaceutical Manufacturing

Sau (Larry) Lee and Kurt Brorson

PDA J Pharm Sci and Tech **2017**, 71 66-67

Access the most recent version at doi:[10.5731/pdajpst.2017.001100](https://doi.org/10.5731/pdajpst.2017.001100)

EDITORIAL

Emerging Technology as a Key Enabler for Modernizing Pharmaceutical Manufacturing

A high-quality drug is generally considered one that is free of contamination and that reliably delivers to the patient the therapeutic benefit as promised on the product label. When patients go to a local pharmacy, they do not inspect individual pills or vials to select the highest quality medicines, like they might do when buying products at the supermarket. Patients implicitly expect the medicine to be of high quality and that it will perform as indicated on the product label every time they take it.

Today's medicines are often the result of intense, cutting-edge basic and clinical research. But alarmingly, drug development globally has tended not to resource the same laboratory-based research and development intensity into pharmaceutical/biopharmaceutical manufacturing as has been placed on drug research and discovery. The manufacture and testing of medicines continues to rely too often on decade(s)-old technologies. Many of the problems that we have seen in drug quality in recent years, including high rates of drug product recalls and shortages, reflect the use of antiquated manufacturing designs and processes. American patients, who face life-threatening conditions such as cancer, infectious disease, and metabolic disorders, suffer enormously when adequate medication runs in short supply.

Within the FDA Center for Drug Evaluation and Research (CDER), the Office of Pharmaceutical Quality (OPQ) oversees several programs to ensure that pharmaceutical products are consistently designed and manufactured to meet patient expectations of drug quality. Recognizing that drug shortages, supply disruptions, and other routes to quality failure might often be overcome through advanced technologies, OPQ seeks to facilitate the moderniza-

tion of pharmaceutical manufacturing. Modern manufacturing technologies have revolutionized other industrial sectors (e.g., electronics and chemicals), and strategic implementation of these technologies in the pharmaceutical industry could well lead to more robust drug manufacturing processes, with fewer interruptions, fewer product failures, and greater assurance that pharmaceutical products manufactured will consistently provide the expected clinical performance. Many technologies also have the potential to increase drug production flexibility and provide scalable response capacity capable of forestalling drug shortages or pandemics.

OPQ understands that the implementation of innovative manufacturing technologies, although desirable and profitable in the long term, may expose companies in the short term with a variety of uncertainties. And for this reason, OPQ is determined that regulatory agility is warranted to facilitate—and not hinder—company efforts to adopt novel or otherwise unfamiliar technologies. OPQ has established its Emerging Technology Program featured by the multidisciplinary Emerging Technology Team (ETT), as described in the draft guidance for industry entitled *Advancement of Emerging Technology Applications To Modernize the Pharmaceutical Manufacturing Base*, to serve as a vehicle for early FDA–sponsor engagement, fostering open communication between the FDA and companies interested in introducing modernizing technologies. The draft guidance can be accessed at <https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm478821.pdf>. Through early engagement and ongoing communication, the ETT will facilitate the development and regulatory assessment of novel manufacturing technologies by proactively identifying and resolving potential scientific and policy issues. The goal of the draft guidance is to provide clarity on the Emerging Technology Program and regulatory process to manufacturers, so that modernization efforts will bring high-quality drug products to market as quickly as possible, without regulatory delays.

* Corresponding Author: Sau (Larry) Lee, Chair of OPQ Emerging Technology Team, Office of Testing and Research, CDER, e-mail: Sau.Lee@fda.hhs.gov
doi: 10.5731/pdajpst.2017.001100

The Emerging Technology Program provides an opportunity, to the benefit of American patients, for companies to accelerate the modernization of pharmaceutical manufacturing. The adoption of innovative manufacturing technologies helps to prevent the types of drug shortages that we have witnessed in recent years. Beyond this, the program may also spark a reinvigoration of our country's

pharmaceutical manufacturing sector and health care mission.

*Sau (Larry) Lee*¹ and Kurt Brorson²*

¹Chair of OPQ Emerging Technology Team Office
of Testing and Research, CDER

²Member of OPQ Emerging Technology Team,
Office of Biotechnology Products, CDER

PDA Journal of Pharmaceutical Science and Technology

An Authorized User of the electronic PDA Journal of Pharmaceutical Science and Technology (the PDA Journal) is a PDA Member in good standing. Authorized Users are permitted to do the following:

- Search and view the content of the PDA Journal
- Download a single article for the individual use of an Authorized User
- Assemble and distribute links that point to the PDA Journal
- Print individual articles from the PDA Journal for the individual use of an Authorized User
- Make a reasonable number of photocopies of a printed article for the individual use of an Authorized User or for the use by or distribution to other Authorized Users

Authorized Users are not permitted to do the following:

- Except as mentioned above, allow anyone other than an Authorized User to use or access the PDA Journal
- Display or otherwise make any information from the PDA Journal available to anyone other than an Authorized User
- Post articles from the PDA Journal on Web sites, either available on the Internet or an Intranet, or in any form of online publications
- Transmit electronically, via e-mail or any other file transfer protocols, any portion of the PDA Journal
- Create a searchable archive of any portion of the PDA Journal
- Use robots or intelligent agents to access, search and/or systematically download any portion of the PDA Journal
- Sell, re-sell, rent, lease, license, sublicense, assign or otherwise transfer the use of the PDA Journal or its content
- Use or copy the PDA Journal for document delivery, fee-for-service use, or bulk reproduction or distribution of materials in any form, or any substantially similar commercial purpose
- Alter, modify, repackaging or adapt any portion of the PDA Journal
- Make any edits or derivative works with respect to any portion of the PDA Journal including any text or graphics
- Delete or remove in any form or format, including on a printed article or photocopy, any copyright information or notice contained in the PDA Journal